GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (LTS:0MTD) » Definitions » Forward PE Ratio
中文

Swedish Orphan Biovitrum AB (LTS:0MTD) Forward PE Ratio

: 27.25 (As of Today)
View and export this data going back to 2010. Start your Free Trial

Swedish Orphan Biovitrum AB's Forward PE Ratio for today is 27.25.

Swedish Orphan Biovitrum AB's PE Ratio without NRI for today is 30.76.

Swedish Orphan Biovitrum AB's PE Ratio for today is 35.24.


Swedish Orphan Biovitrum AB Forward PE Ratio Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Annual Data
Trend 2015-12 2016-11 2017-12 2018-12 2019-12 2020-12 2021-12 2022-12 2023-12 2024-04
Forward PE Ratio
66.23 23.31 15.95 19.61 10.92 15.29 23.87 16.61 21.23 26.74

Swedish Orphan Biovitrum AB Quarterly Data
2015-12 2016-06 2016-09 2017-06 2017-09 2017-12 2018-03 2018-06 2018-09 2018-12 2019-03 2019-06 2019-09 2019-12 2020-03 2020-06 2020-09 2020-12 2021-03 2021-06 2021-09 2021-12 2022-03 2022-06 2022-09 2022-12 2023-03 2023-06 2023-09 2023-12 2024-03
Forward PE Ratio 66.23 32.15 25.64 31.95 22.62 15.95 24.39 25.97 25.97 19.61 22.22 17.54 15.60 10.92 15.90 19.92 21.41 15.29 20.58 22.52 32.36 23.87 22.08 25.00 16.08 16.61 19.72 17.79 16.13 21.23 27.62

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB Forward PE Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Forward PE Ratio falls into.



Swedish Orphan Biovitrum AB Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Swedish Orphan Biovitrum AB  (LTS:0MTD) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Swedish Orphan Biovitrum AB Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB (LTS:0MTD) Business Description

Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB (LTS:0MTD) Headlines

No Headlines